(firstQuint)Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy.

 Patients are randomized in a 2:1 scheme to 1 of 2 treatment groups.

 Group 1 receives GW433908 plus abacavir (ABC) plus lamivudine (3TC); Group 2 receives nelfinavir (NFV) plus ABC plus 3TC.

 Patients undergo safety and efficacy assessments at the Screening Visit, Day 1 (Entry), and Weeks 1, 2, 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter.

 A follow-up visit is performed 4 weeks after the permanent discontinuation of study drug.

 Detailed assessments for the development of lipodystrophy/fat redistribution occur at Day 1, Week 24, Week 48, and every 16 weeks thereafter.

 Patients have examinations and laboratory tests performed at visits.

.

 Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy@highlight

The purpose of this study is to compare GW433908 and nelfinavir when each is given with abacavir and lamivudine to HIV patients who have not taken antiretroviral drugs.

